INO 外匯新聞
Inovio Pharma Receives FDA Feedback On Submission Of BLA For INO-3107 To Treat RRP
Biotechnology company Inovio Pharmaceuticals, Inc. (INO) announced Tuesday that it has received feedback from the U.S. Food and Drug Administration (FDA) that data from its completed Phase 1/2 trial of INO-3107 for the treatment of RRP could support INOVIO's submission of a BLA for review under the FDA's accelerated approval program.
RTTNews
|
479天前
INOVIO Says FDA Grants Breakthrough Therapy Designation For INO-3107; Stock Up 15%
Biotechnology company Inovio Pharmaceuticals, Inc. (INO) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for INO-3107 as a potential treatment for patients with Recurrent Respiratory Papillomatosis (RRP).
RTTNews
|
512天前
INOVIO Pharma Announces Positive Results From Phase 1b Clinical Trial Evaluating INO-4201
Biotechnology company INOVIO Pharmaceuticals, Inc. (INO) announced Thursday positive results from a Phase 1b clinical trial evaluating INO-4201, a DNA vaccine candidate, as a booster in healthy adult participants who previously received a single injection of Ervebo.
RTTNews
|
729天前
INOVIO Reports Positive Interim Phase 1/2 Trial Results For INO-3107 For Respiratory Papillomatosis
Biotechnology company Inovio Pharmaceuticals Inc. (INO) announced Thursday positive interim results from an ongoing Phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) in adults.
RTTNews
|
841天前
INOVIO Announces Corporate Reorganization, Including Workforce Reduction, To Reduce Expenses
Biotechnology company INOVIO (INO) announced Tuesday that it has implemented a corporate reorganization designed to extend its cash runway and to focus on key clinical programs with the goal to drive long-term growth.
RTTNews
|
927天前
